Amelie Harle, MD, of the Christie NHS Foundation Trust, discusses a clinical trial––the first of its kind—designed to assess the efficacy of an antitussive in patients with lung cancer (Abstract 2).
Eduardo Bruera, MD, of The University of Texas MD Anderson Cancer Center, discusses exciting developments in the assessment and management of cachexia, as well as a number of emerging pharmacologic and nonpharmacologic interventions (Abstract 67).
Ralph J. Hauke, MD, of Nebraska Cancer Specialists, discusses the application of scientific analysis and research to palliative care issues, which will allow better prognostication, implementation of measures, and improved quality of life.
Diane Portman, MD, of Moffitt Cancer Center, discusses clinical pathways that embed palliative care along the spectrum of care for a variety of cancer disease states.
Judith Vick, MD Candidate, of Johns Hopkins University School of Medicine, and Rachelle E. Bernacki, MD, of Dana-Farber Cancer Institute, discuss a tool that could help clinicians identify seriously ill patients who would benefit from conversations about their goals and values (Abstract 8).
Kathleen Elizabeth Bickel, MD, MPhil, of the White River Junction VA Medical Center, discusses the ASCO/AAHPM Guidance Statement, which will help oncology providers enhance their delivery of palliative care (Abstract 108).
